REGULATORY, HTA & EVIDENCE STRATEGY
We align approval, reimbursement, patient value and future clinical
relevance before pivotal assumptions become expensive to change.
THE EVIDENCE QUESTION
Build the evidence package needed
for regulatory credibility.
Anticipate payer, HTA and
comparative-value expectations.
Protect post-approval clinical
and strategic usefulness.
OUR EVIDENCE PATHWAY
Clarify disease context,
stakeholders and
evidence needs.
Analyse regulatory, HTA
and clinical expectations
across markets.
Define a cohesive
evidence strategy and
value narrative.
Design and support
evidence generation
(clinical, RWE, HEOR).
Prepare for submissions,
HTA reviews and
value discussions.
Maintain and evolve
evidence for lifecycle
opportunities.
WHAT WE OFTEN CHANGE FIRST
From regulatory-friendly but payer-irrelevant endpoints to fit-for-purpose evidence.
From suboptimal comparators to clinically and economically credible comparisons.
From technical data to a clear, differentiated value proposition.
From late surprises to proactive alignment with HTA requirements and local nuances.
From a single submission mindset to a long-term evidence strategy across indications and settings.
Copyright © 2026 Manolo Beelke & Partners. All rights reserved.
